Two Sigma Securities LLC Has $3.59 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Two Sigma Securities LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 407.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,761 shares of the biopharmaceutical company’s stock after purchasing an additional 4,626 shares during the quarter. Two Sigma Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $3,592,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in REGN. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. Dodge & Cox lifted its position in Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Franklin Resources Inc. lifted its position in Regeneron Pharmaceuticals by 4.4% in the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC boosted its stake in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $794.19 on Monday. The business’s 50 day simple moving average is $717.52 and its 200 day simple moving average is $717.95. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The company has a market cap of $81.77 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 1.35 and a beta of 0.22. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the business posted $12.81 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, Truist Financial raised their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Fifteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.